Related Experiment Videos
Gallium nitrate for the treatment of bone metastases
1Department of Medicine, Memorial Sloan-Kettering Cancer Center, and the Cornell University Medical College, New York, New York 10021, USA.
Abstract:
Gallium nitrate was originally developed as an antineoplastic agent; however, further studies have revealed that this drug has extremely potent effects on turnover of bone, and that low doses can be used to reduce bone resorption. Like the bisphosphonates, gallium nitrate has been studied in both malignant and in nonmalignant conditions. The results of randomized double blind studies have suggested that this drug has superior clinical efficacy relative to etidronate, calcitonin, and pamidronate for the acute control of cancer-related hypercalcemia. In patients with Paget's disease, low doses of gallium nitrate reduce biochemical parameters of accelerated bone turnover, including urinary excretion of calcium, hydroxyproline, and urinary collagen cross-linked N-telopeptides. Preliminary studies showed similar effects in patients with bone involvement from a wide variety of tumor types. Based on this high degree of clinical potency revealed in clinical studies, two randomized Phase III studies have been initiated in patients with bone metastases from breast carcinoma and bone involvement due to multiple myeloma. Both studies employ cyclic therapy with low dose gallium nitrate (i.e., 40 mg administered as a subcutaneous injection once daily for 2 weeks, followed by 2 weeks off treatment, recycled monthly). The endpoints of both studies are to document reductions in time to "morbid skeletal events," such as palliative skeletal radiotherapy, stabilizing orthopedic surgery, or pathologic fractures, as well as decreases in pain and analgesic requirements and improvements in mobility and other aspects of quality of life. These trials should provide definitive evidence of whether this agent is safe and effective as a treatment for bone metastases.
Insights
Gallium nitrate effectively reduces bone resorption and hypercalcemia in cancer patients. Ongoing trials investigate its efficacy in preventing skeletal events in breast cancer and multiple myeloma bone metastases.
Area of Science:
- Oncology
- Pharmacology
- Bone Metabolism
Background:
- Gallium nitrate, initially an antineoplastic agent, demonstrates potent effects on bone turnover.
- Low-dose gallium nitrate effectively reduces bone resorption, similar to bisphosphonates.
- Clinical studies indicate superior efficacy over etidronate, calcitonin, and pamidronate for hypercalcemia control.
Purpose of the Study:
- To evaluate the efficacy of low-dose gallium nitrate in managing bone metastases.
- To assess the drug's impact on skeletal morbidity and quality of life in cancer patients.
- To provide definitive evidence on the safety and effectiveness of gallium nitrate for bone metastases.
Main Methods:
- Two randomized Phase III studies initiated for breast carcinoma and multiple myeloma bone metastases.
- Cyclic therapy with low-dose gallium nitrate (40 mg daily for 2 weeks, then 2 weeks off).
- Endpoints include time to morbid skeletal events, pain reduction, and quality of life improvements.
Main Results:
- Gallium nitrate shows potent effects on bone turnover and reduces bone resorption.
- Effective in controlling cancer-related hypercalcemia, outperforming other agents.
- Low doses reduce biochemical markers of bone turnover in Paget's disease and various tumor types.
Conclusions:
- Gallium nitrate is a potent agent for managing bone turnover and hypercalcemia.
- Ongoing Phase III trials will determine its role in treating bone metastases.
- Potential to reduce skeletal morbidity and improve quality of life in cancer patients with bone involvement.